ADMA ADMA BIOLOGICS, INC. Insider Trading

Director Jerrold B Grossman buys 6,400 ADMA shares at $7.91; stock down -64.6% from 52-week high of $22.37

Jerrold B Grossman, a director, purchased 6,400 shares at $7.91 on 2026-05-27, increasing his holdings to 520,284 shares. This occurs as ADMA trades at $7.93, representing a significant decline of -64.6% from the 52-week high of $22.37 and a 90-day decline of -49.1%. Grossman's cross-ticker track record shows mixed results: his 3 prior buys averaged -1.1% returns over 90 days with a 0.00% win rate, while his same-ticker history at ADMA includes two recent purchases (2026-05-12 and 2026-05-11) that each returned -1.1% over 90 days. The company's fundamentals remain solid with revenue of $114,493,000.00, net income of $45,328,000.00, a P/E of 11.17, and annual revenue growth of +19.6%, but the substantial stock price decline raises questions about market confidence despite operational performance.

ADMA Biologics director Grossman buys 12,500 shares in 3rd open-market purchase at ADMA in under 3 years, adding to position near 52-week lows

Director Jerrold B. Grossman made his third open-market purchase of ADMA Biologics shares in the 36-month window, acquiring 12,500 shares and expanding his direct stake from roughly 501,000 to nearly 514,000 shares. The stock is trading sharply below its 52-week high and near its 52-week low, having declined substantially over both the past month and the past three months — meaning Grossman is stepping into meaningful recent weakness. ADMA Biologics is a profitable company with growing annual revenue, and its valuation appears modest relative to its earnings, which provides some fundamental backdrop for a director's open-market commitment. Grossman's same-ticker track record shows mixed results: his one evaluated prior buy at this stock was well-timed at both the 30-day and 90-day marks, while his one evaluated prior sell was poorly timed — the stock rose significantly in the months that followed. Taken together, the director is a repeat open-market buyer at this company whose single evaluated prior buy produced a positive outcome, though his selling record at this ticker has been less accurate, making the overall track record mixed.

Director Jerrold B Grossman purchases 12,500 ADMA shares at $8.01 as stock trades well below 52-week highs amid broad decline.

Jerrold B Grossman, a director of ADMA Biologics, purchased a substantial position of 12,500 shares at prices near the 52-week low, following a sharp stock decline. This marks his second open-market purchase in the past three years, adding to prior buying activity. The timing is contrarian—he is buying into weakness at a point where the stock has fallen sharply from its 52-week high. However, his track record offers a cautionary note: his most recent prior sale in this stock was poorly timed, as the stock rose significantly afterward, suggesting limited accuracy in read ng the company's trajectory. ADMA remains a profitable company with growing revenue, yet the director's purchase arrives during an extended pullback, buying shares at depressed levels rather than at prior peaks.

Director Steve Elms buys 14,000 shares (2 transactions, $217.4K) at $15.67 and $15.39, near 52-week low amid -20.2% 90-day decline.

Director Steve Elms purchased 14,000 shares across 2 separate transactions totaling $217,420.00, with a blended average price of $15.53. The purchases occur as ADMA trades near the lower end of its 52-week range ($13.99–$24.51), down 35.5% from the 52-week high and down 20.2% over the past 90 days. Elms' prior open-market trading shows 1 prior buy with a 100% 90-day win rate (+5.3% return), though his cross-ticker sell history has been less favorably timed (37.50% well-timed rate). At the same ticker, Elms' 5 prior trades (all sales) show a 3 of 5 pattern of well-timed exits, with recent June 2025 sales capturing declines. This buy adds 14,000 shares to his post-transaction total of 2,045,730 shares, a 0.7% increase in holdings. The company's fundamentals remain solid—$134.2M latest quarterly revenue, net income of $36.4M, +19.6% annual revenue growth, and a P/E of 23.60—providing a backdrop for the purchase decision at depressed prices.

Director Steve Elms sold 425,621 shares of ADMA for $8,829,333.47 across 3 days, reducing holdings 83%

Director Steve Elms executed 3 separate sales totaling 425,621 shares for $8,829,333.47 over a three-day window (June 12–16, 2025), with prices ranging from $20.24 to $21.69 and a blended average of $20.74. This sale reduced his holdings from 512,951 shares to 87,330 shares, a -83.0% reduction in his stake. The timing is notable: his prior 5 sales at ADMA (March 2024) all resulted in 90-day gains of +69.1% to +79.4%, meaning the stock rose significantly after each prior sale—a pattern of poorly-timed exits. His cross-ticker track record shows 5 prior sells with a 0.00% well-timed rate (no negative post-sale returns observed), reinforcing a pattern where subsequent price appreciation has followed his sales. The company's current fundamentals are strong (P/E of 23.45, +65.2% annual revenue growth, $26.9M net income in the latest quarter), and the stock is trading near its 52-week high at $20.40, only -16.8% below the $24.51 peak. The scale and speed of this divestment—83% of his prior position—stands in contrast to the company's solid operational performance.

Director Grossman sells 136.9K ADMA shares at $17.27, reducing stake to 467.3K shares; stock up 41% in 30 days.

Director Jerrold B Grossman sold 136,861 shares at $17.27, representing a 22.7% reduction in his stake from 604,166 to 467,305 shares. The sale occurred as ADMA's stock has appreciated significantly—up 41.0% in the prior 30 days and 81.3% over 90 days—though the price remains 5.9% below its 52-week high of $18.40. Historically, Grossman's prior transaction at this ticker (a buy on 2023-08-30) achieved a 90-day return of +0.3%, marking one of one well-timed buys at ADMA. The company shows strong near-term revenue growth (+67.6% annual) and a recent profitable quarter ($32.1M net income), though it carried negative full-year net income historically. The elevated P/E of 115.40 and current momentum warrant focus on whether the stock's sharp gains represent sustainable value or timing-driven appreciation.

CEO Adam S Grossman sold 236,889 shares of ADMA at $17.69 on 2024-08-26 for $4,191,087.57.

CEO Adam S Grossman executed a sale of 236,889 shares at $17.69, reducing his holdings from 2,685,971 shares to 2,449,082 shares—a reduction of 8.8% of his pre-transaction stake. The transaction generated $4,191,087.57 in proceeds. While the sale represents a material reduction in his proportional ownership, the CEO retained 2.45M shares post-transaction, indicating a continued substantial equity stake in the company. The data reflects a discrete insider transaction; without additional context regarding whether this sale was scheduled under a 10b5-1 plan, discretionary market conditions, or other factors, the filing itself provides the transaction fact but not the underlying motivation.

Director Kwon Young sold 60,000 shares of ADMA at $18.26 on 2024-08-23, reducing stake by 19.9% to 241,441 shares.

Director Kwon Young executed a substantial sale of 60,000 shares at $18.26, representing a 19.9% reduction in holdings and totaling $1,095,600.00. The transaction occurred near the stock's 52-week high of $18.40, where ADMA has rallied 31.8% over the preceding 30 days and 84.6% over 90 days. However, the company's fundamentals present a mixed picture: while revenue reached $107,191,000.00 with net income of $32,062,000.00 in the latest quarter and annual revenue growth accelerated to 67.6%, the full fiscal year remains unprofitable with a P/E of 115.67 reflecting elevated valuation expectations. This substantial directed sale during a sharp price recovery warrants investor attention regarding insider perspective on current valuations relative to operational profitability.